optima-logo.png
Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302
October 04, 2021 07:00 ET | Opthea Limited
MELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea To Present at September Investor Conferences
September 02, 2021 07:00 ET | Opthea Limited
MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
optima-logo.png
Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights
August 30, 2021 07:00 ET | Opthea Limited
Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD) OPT-302 Granted FDA Fast Track Designation for Wet AMD Received FDA Waiver for Pediatric...
optima-logo.png
Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 10, 2021 07:00 ET | Opthea Limited
MELBOURNE, Australia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
optima-logo.png
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
August 09, 2021 07:00 ET | Opthea Limited
MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration
July 06, 2021 07:00 ET | Opthea Limited
MELBOURNE, Australia, July 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Appoints Company Secretary and Vice President of Finance
June 14, 2021 07:00 ET | Opthea Limited
MELBOURNE, Australia, June 14, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors
June 01, 2021 07:11 ET | Opthea Limited
Board expands strengths in clinical and commercialization strategy OPT-302 pivotal Phase 3 trials for wet age-related macular degeneration (AMD) on track to reporting top-line data in 2023 ...
optima-logo.png
Opthea Company Secretary Resignation
April 06, 2021 05:30 ET | Opthea Limited
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of...
optima-logo.png
Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD
March 31, 2021 05:30 ET | Opthea Limited
MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and...